Abstract：【Objective】 To investigate the clinical effect of compound salvia miltiorrhiza(Danshen) pills in the treatment of diabetic retinopathy(DR). 【Methods】 The clinical data of 106 patients with DR from March 2015 to October 2017 were divided into observation group and control group with 53 cases in each group. The patients in the control group were treated with hypoglycemic, acid-base balance, and the observation group was treated with compound salvia miltiorrhiza pills on the basis of the control group. The therapeutic effect, visual field grayscale, hemangioma volume, macular area, macular thickness, serum interleukin-6 (IL-6), tumor necrosis factor (TNF-α),high sensitivity C-reactive protein (hs-CRP), plasma endothelin-1 (ET-1), vascular endothelial growth factor (VEGF), reactive oxygen (ROS) were observed. The levels of superoxide dismutase (SOD) and malondialdehyde (MDA) (MDA) were measured by spectrophotometer.【Results】 The total effective rate was 90.57% (48 / 53) in the observation group and 77.36% (41/53) in the control group (P<0.05). The visual field grayscale, hemangioma volume, macular area, macular thickness, serum hs-CRP, IL-6,TNF-αand ET-1, VEGF, ROS, MDA levels were significantly lower in both groups than before treatment, and SOD was significantly higher than that before treatment. The improvement in the observation group was more significant than that in the control group, and the difference was statistically significant (P<0.05). There were no obvious adverse drug reactions in both groups during treatment.【Conclusion】 Compound salvia miltiorrhiza (Danshen) pills can improve the clinical efficacy, improve the symptoms of visual field defect, down-regulate the inflammatory index, improve vascular endothelial function, alleviate oxidative stress state, and the safety is good. It is worth popularizing in clinical application.
2019, Vol. 36 
